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Abstract
Skeletal muscle atrophy can occur at any age and as a result of numerous physiological conditions and
thus, it was necessary to better identify the molecular underpinnings of the atrophy cascade so that new
therapeutic targets to treat muscle wasting might be identified. MuRF1 was first identified as a marker of
skeletal muscle atrophy over a decade ago; however, recent work suggests that this E3 ubiquitin ligase
may participate in muscle wasting by regulating the transcriptional activity of genes differentially
expressed in response to muscle atrophy. Dusp4, a dual-specificity phosphatase and member of the
MAPK cascade, is induced in response to neurogenic atrophy; however, this induction is significantly
blunted in the MuRF1-null mice which are resistant to muscle atrophy. The research presented in this
thesis aims to characterize the mechanism by which MuRF1 may transcriptionally regulate Dusp4 and
characterizes the function of Dusp4 in skeletal muscle.
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Chapter 1: Background of Skeletal Muscle Atrophy and the Role of MuRF1
Skeletal Muscle Physiology and Muscle Atrophy
The maintenance of healthy skeletal muscle is a dynamic process that requires the muscle tissue to sense
and interpret signals from the surrounding environment and integrate those signals into action. This
interpretation works to either increase protein turnover (atrophy) or protein synthesis (hypertrophy)
depending on cues received in response to physiological and/or pathological conditions. Continuous
restructuring occurs within the skeletal muscle tissue that depends on a careful balance between protein
synthesis and protein degradation, a balance that may shift depending on the physiological needs of the
individual [1]. Muscle hypertrophy, an increase in muscle fiber size, occurs when there is a shift towards
protein synthesis that happens most commonly during development [2]. Skeletal muscle atrophy occurs
when the individual myofibers experience increased protein turnover and decreased protein synthesis that
results in a decrease in size, net force production, and elevated muscle fatigue [3]. Muscle atrophy may
result from a variety of physiological conditions including limb immobilization, cancer (cachexia), aging
(sarcopenia), corticosteroid use, and denervation [4]. The molecular mechanisms that regulate different
types of muscle atrophy (disuse, malnutrition, or neurogenic pathologies) can vary widely and the cellular
cascade of events, including gene regulation or induction of reactive oxygen species (ROS), all lead to
increased protein degradation and a reduction in muscle fiber size [5, 6]. Although initial research in the
field of skeletal muscle wasting focused on protein turnover, understanding the complete molecular
signaling processes that leads to the phenotype of atrophy has been difficult to define completely.

Skeletal muscle wasting is observed in many conditions that plague human health including patients
suffering from stroke, burns and arthritis; however, neurogenic atrophy which is the most severe form can
be found in patients with Guillain-Barre syndrome, multiple sclerosis, and Lou Gehrig’s disease [7].
There is no repair system in humans that facilitates the repair of damaged nerves which connect to
muscles. In lower vertebrate organisms, such as mice, damaged neurons have a unique plasticity and can
reestablish neural connections with skeletal muscle myofibers following a traumatic event due to the

presence of neural stem cells; this phenomenon does not exist in higher mammals, such as humans [8].
Identifying the pathways linking regenerative neural plasticity to skeletal muscle fibers would offer many
new therapeutic opportunities for people suffering from severe muscle wasting. One potential regulatory
mechanism that has the ability to alter the differentiated state of committed myotubes is through the
influence of myogenic regulatory factors (MRF), myogenin and MyoD1, which are responsible for
transcriptional regulation of muscle specific genes. In the murine model, down-regulation of myogenin
reverses terminal muscle cell differentiation [9] and in myofibroblasts reduction of MyoD1 results in cells
de-differentiating and re-entering the cell cycle [10]. Current research has focused on characterizing the
molecular mechanisms of skeletal muscle atrophy in cell culture models, potentially leading to the
identification of new drug targets and therapies.

Identification of Markers of Skeletal Muscle Wasting
The first step in unraveling the physiological mystery of muscle atrophy was to identify molecular
mediators, particular genes with significant differential expression in response to a range of disparate
conditions known to induce atrophy. To this end, a differential expression study was conducted using
gastrocnemius muscle isolated from Sprague-Dawley rats that were subjected to hind limb suspension,
limb immobilization, or sciatic nerve denervation in order to promote skeletal muscle wasting [11]. A
total of 74 genes showed alterations in activity under one or two conditions but only two genes, muscle
RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx) showed increased gene expression under all
conditions (Figure 1) [11]. These findings helped to identify MuRF1 and MAFbx as hallmark genetic
markers in the overall process of skeletal muscle atrophy. Additional research has shown that MuRF1null and MAFbx-null mice are resistant to most forms of skeletal muscle wasting compared to the wildtype mice further demonstrating the importance of these genes in the muscle atrophy signature [11].
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Figure 1. mRNA expression profiles of MuRF1 and MAFbx in Sprague-Dawley rat gastrocnemius muscle
under muscle atrophy conditions. MuRF1 and MAFbx showed increased expression following limb
immobilization, sciatic nerve denervation, and hind limb suspension by day 1 with maximum expression reached by
3 days. Numbers represent the number of days post-denervation. (Adapted from Bodine, et al., 2001)

MuRF1 and the Ubiquitin-Proteosome System (UPS)
MuRF1 and MAFbx were identified as markers of skeletal muscle atrophy following experimentation
which evaluated conditions known to induce atrophy such as immobilization, sciatic nerve denervation,
and hind limb unweighting [11]. The identification of two genes, both of which are E3 ubiquitin ligases,
began the long journey to identify protein targets following an atrophy-inducing stimulus. The increased
expression of MuRF1, which is believed to participate in the ubiquitin-proteasome system (UPS),
provides an attractive model for how MuRF1 might function during muscle wasting and may help explain
the decrease in muscle fiber size which is known to occur during skeletal muscle atrophy [12].

Muscle breakdown and protein turnover is coupled with increased activity of the ubiquitin-proteasome
system [13]. The UPS is an ATP-dependent system composed of an E1 ubiquitin-activating enzyme, an
E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin ligase that function in tandem to covalently tag
proteins with ubiquitin and subsequently target them for breakdown by the 26S proteasome (Figure 2)
[14-16]. The ubiquitin-proteasome system and the subsequent turnover of damaged or unneeded proteins
occurs normally; however, it is the up-regulation of these processes during skeletal muscle atrophy that
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has garnered interest and has pushed the research focus towards elucidating the molecular mechanisms of
muscle wasting, including transcriptional regulation of genes and post-translational modification of
proteins, that remain uncharacterized in the progression of muscle atrophy [17].

Figure 2. Schematic of the ubiquitin-proteasome system. Protein degradation by the proteasome involves
collaboration of three enzymes; a ubiquitin activating enzyme (E1), a ubiquitin conjugating enzyme (E2) and a
ubiquitin ligase (E3). (Open access image created by Roger Dodd)

Identification of Differentially Expressed Genes Following Neurogenic Atrophy
Given that muscle-specific E3 ligases show increased expression following neurogenic atrophy and that
MuRF1 knock-out animals are resistant to muscle wasting, a microarray using gastrocnemius muscle
obtained from wild-type (WT) and MuRF1-null (KO) mice was performed following sciatic nerve
denervation in order to evaluate global changes in gene expression [18]. MuRF1 gene expression
increased in the wild-type animals at 3 days post-denervation, but returned to baseline levels by 14 days
post-denervation; however, β-galactosidase expression, that was controlled by the intact MuRF1
promoter, was up-regulated following denervation at 3 days and remained elevated at 14 days postdenervation (Figure 3) [18]. Numerous genes involved in cellular proliferation, differentiation, apoptosis,
DNA packaging, muscle-specific transcription factors as well as the mitogen-activated protein (MAP)
4

kinase cascade showed differential expression following denervation; however, some of the observed
changes in gene activity were altered in the animals lacking MuRF1 expression [18]. Whether MuRF1 is
necessary for the direct transcriptional regulation of these genes or whether MuRF1 may modulate
separate transcription factors important for gene activity has yet to be determined.

Figure 3. MuRF1 and β-galactosidase expression profiles in wild-type (WT) and MuRF1-null (KO) mice. (A)
MuRF1 gene expression increased following denervation in WT animals at 3 days and returned to baseline levels by
14 days post-denervation. (B) β-galactosidase expression, which is under the control of the MuRF1 gene promoter,
showed increased expression following 3 days of denervation and remained elevated at 14 days post-denervation.
Error Bars represent standard deviation.

Myogenic Regulatory Factors Control Tissue Development
Myogenin and MyoD1 are muscle-specific transcription factors that are referred to as myogenic
regulatory factors (MRF) (Figure 4) [19]. MRFs contain the basic helix-loop-helix (bHLH) motif
consisting of two α-helices connected by a loop [20]. Myogenin is expressed early during the
developmental stage and is required for viable embryonic myofiber formation; additionally, myogenin is
upregulated following damage to the muscle and helps aid in regenerating damaged muscle tissue [13, 20,
21]. MyoD1 is also important for muscle cell regulation as it functions in the myogenic determination of
myoblasts [22]. Interestingly, differentiated myofibroblasts subjected to MyoD1 knock-down were able to
dedifferentiate and reenter the cell cycle mimicking the undifferentiated myoblast stage [10]. Down
regulation of myogenin reverses terminal muscle cell differentiation [9], therefore we believed it was
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important to this study to assess the effects that both myogenin and MyoD1 have on the regulation of
Dusp4 transcriptional activity in skeletal muscle cells.

Graphic redacted, paper copy available upon request to home institution.

Figure 4. Model of skeletal muscle myogenesis. The growth of uncommitted mesodermal cells into committed
myotubes depends on cellular signaling from transcription factors including Pax3, Pax7, MyoD1, and myogenin.
MyoD1 aids in the commitment from satellite cells to un-differentiated muscle myoblast cells whereas myogenin
functions to regulate the formation of differentiated myotubes (Image adapted from Hettmer and Wagers, 2010 .)

Muscle tissue requires MRF expression in order to maintain the differentiated, multi-nucleated mature
muscle fibers that are necessary for motor function and muscle contraction [23]. The microarray that was
performed to evaluate global changes in gene expression following denervation-induced skeletal muscle
atrophy shows that two myogenic regulatory factors, MyoD1 and myogenin, were markedly increased at
both 3 days and 14 days post-denervation compared to non-denervated wild-type littermates (Figure 5).
Although MyoD1 expression was increased at 14 days post-denervation, there was blunted induction at
14 days in the MuRF1-null animals. A similar trend was observed for myogenin which showed increased
expression at 3 and 14 days post-denervation in both WT and KO animals; however, the increase in
myogenin expression was blunted in the MuRF1-null animals (Figure 5). The increase in these two
important transcription factors, which are necessary to maintain the differentiated status of skeletal
muscle cells, shows that the presence of functional MuRF1 protein may be needed for full activation of
MRFs after a denervation event.
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Figure 5. Myogenic regulatory factors show increased mRNA expression in response to sciatic nerve
denervation. MyoD1 and myogenin expression increased at both 3 and 14 days following denervation in wild-type
and MuRF1-null mice. Error bars represent ± standard deviation.

Dusp4 Expression Increases Following Neurogenic Muscle Atrophy
One gene from the microarray described above that was significantly up-regulated at both 3 and 14 days
following sciatic nerve denervation was dual-specificity phosphatase 4 (Dusp4) (Figure 6). Dusp4 is a
member of the mitogen activated protein (MAP) kinase cascade which functions to control numerous
cellular processes ranging from proliferation, differentiation and apoptosis in the maintenance of cellular
homeostasis [24]. Dusp4 has been the focus of cancer research due to its role in proliferation and
apoptosis in lymphatic tissue as well as in the brain [25, 26]; however, little work has been performed to
identify what role it may play in the formation of myotubes and the development of healthy skeletal
muscle. Increased Dusp4 activity has previously been linked to the inflammatory response as well as to
cell cycle signaling by controlling the G2/M phase transition, but the role of Dusp4 in skeletal muscle has
not been well characterized [26, 27].

7

B

A

Dusp4 Probe 2690044

700
600

Innervated

1800

*

Denervated

500

400
300

*

*

200
100

0
WT 3D

KO 3D

WT 14D

KO 14D

Dusp4 Probe 100630110

2000
Average Expression (mean ± SD)

Average Expression (mean ± SD)

800

1600

*
Innervated
Denervated

1400
1200
1000
800
600

*
*

400

*

200
0
WT 3D

KO 3D

WT 14D

KO 14D

Figure 6. Dusp4 expression profiles in wild-type (WT) and MuRF1-null (KO) mice. Whole genome expression
analysis was conducted on gastrocnemius muscle from WT and KO mice following 3 days (3D) and 14 days (14D)
denervation. Each condition was conducted in triplicate and the expression is the average of three individual mice.
The error bars represent ± standard deviation. The microarray had two separate Dusp4 probes and both probes listed
above showed similar expression profiles. Dusp4 expression increased significantly following denervation in WT
mice at both 3 and 14 days, however expression was significantly suppressed in the MuRF1-null mice following
denervation when compared to the WT mice (* p ≤ 0.05 Two tailed T-test).

Dusp4 is a dual-specificity phosphatase that exhibits the ability to dephosphorylate both threonine and
tyrosine residues of phosphate-activated MAP kinases. The Dusp4 protein is composed of an N-terminal
MAP kinase binding domain, two cdc25 homology domains that are found in all mitogen-activated
protein kinase phosphatases (MKPs) which reflect their common evolutionary origin, a C-terminal
catalytic phosphatase domain that has conserved aspartic acid (D), cysteine (C), and arginine (R) residues
that form the catalytic phosphatase pocket, and an N-terminal nuclear localization signal (NLS) making
Dusp4 a type-1 dual specificity phosphatase (Figure 7) [28-30].

Depending on the cell type, Dusp4 has the ability to inactivate MAPK’s such as extra-cellular signal
related kinase (ERK), c-jun related kinase (JNK), and p38 [31, 32]. The substrate specificity may be
tissue specific, since previous research suggests that Dusp4 has the ability to dephosphorylate all three
MAPK’s while other research suggests its function is restricted to dephosphorylating only ERK [24, 31].
Furthermore, research suggests that after Dusp4 removes the activated phosphate group from ERK, the
dephosphorylated ERK then translocates back to the cytoplasm to wait for an additional signaling
response while Dusp4 remains located in the nucleus, due to its nuclear localization signal [33].
8

Figure 7. Schematic of the different classes of dual-specificity phosphatases. Dusp4 is a class 1 dual-specificity
nuclear phosphatase which contains two cdc25 domains, an N-terminal MAP kinase interacting motif (KIM), an Nterminal nuclear localization signal (NLS), and a C-terminal catalytic phosphatase domain. (Adapted from Lawan, et
al., 2011.)

The focus of this study was to ascertain the function of Dusp4 in skeletal muscle, since it was found to be
up-regulated following sciatic nerve denervation and has not been previously characterized in muscle
tissue (Figure 6) [18]. Developing a better understanding of how the Dusp4 gene is regulated by MuRF1,
as well as MRFs, and characterizing the functional role of Dusp4 in skeletal muscle may help to clarify
why increased Dusp4 expression is observed following denervation. The possible interaction between
MuRF1 and the MRFs, which bind to E-box elements located in the Dusp4 promoter, is a potential way
by which MuRF1 may alter Dusp4 gene expression (Figure 8). Additionally, the timing of Dusp4 protein
expression in muscle was evaluated by western blot using C2C12 cells and was found to be expressed in
proliferating myoblasts, but not differentiated myotubes. Finally to confirm the sub-cellular location of
Dusp4 in myoblasts, the cDNA of Dusp4 was engineered with a green fluorescent protein (GFP) tag and
9

visualized using confocal microscopy revealing that Dusp4 is localized exclusively to the nucleus. The
information obtained in this study helps characterize the transcriptional regulation of Dusp4 and helps
determine the function of Dusp4 in muscle in response to denervation and provides evidence for the
potential physiological importance of this gene in skeletal muscle.

Figure 8. Schematic of the MAP kinase pathway. The diagram illustrates both the cytoplasmic and nuclear
portions of this signaling pathway in response to denervation as well as cellular signaling. During normal cellular
conditions Dusp4 dephosphorylates phosphate-activated nuclear MAP kinases (ERK, JNK, and p38) which results
in the inactivation of MAPK responsive genes. Following neurogenic atrophy, MuRF1, myogenin, and MyoD1 are
upregulated which results in Dusp4 repression. This reduction in Dusp4 activity could result in increased MAPK
phosphorylation leading to the activation of MAPK responsive genes.
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Chapter 2: Characterization of the Transcriptional Regulation and Function of Dusp4 in Skeletal
Muscle
Overview
Protein phosphorylation represents a critical event in the activation and regulation of a variety of cellular
pathways. The mitogen-activated protein (MAP) kinase cascade represents an important step that can alter
gene expression profiles and change the behavior of cells. MAP kinase kinase kinases (MAPKKK)
phosphorylate MAPKKs, which in turn phosphorylate and activate MAPKs [33]. In mammalian cells,
there are four MAPK families: extra-cellular signal-related kinase 1/2 (ERK 1/2), ERK5, p38, and c-jun
N-terminal kinase (JNK) [34]. MAP kinases such as ERK, p38, and JNK can be phosphorylated on
threonine or tyrosine residues [35]. The MAP kinase contains a core Thr-X-Tyr (TXY) motif in which
threonine or tyrosine residues may be phosphorylated although it may be necessary for both amino acids
to be phosphorylated for full activity [31]. The central amino acid (X) may be either a glutamine, proline,
or another tyrosine residue, in ERK, JNK, or p38 MAP kinases [28]. The particular amino acid that
becomes phosphorylated may play a pivotal role in the function of the MAPK or may dictate other
binding partners for further regulation [36]. Activated MAPKs have the ability to translocate from the
cytoplasm to the nucleus where they can phosphorylate serine, threonine, or tyrosine residues of other
proteins, namely transcription factors, that directly affect gene regulation [35]. Because of their role in
ligand-activated signal transduction pathways, MAP kinases play important roles in stress response,
cellular regeneration, differentiation, metabolic diseases, and cancer [37].

Due to the energy requirements for transcription and translation of a protein, it is important to ensure that
cellular signals instructing protein synthesis are indeed necessary. At each step of the MAP kinase
cascade, in addition to the kinases required for further activation of the pathway, there are also
phosphatases that remove phosphate groups from proteins, thus inactivating the signal. The dualspecificity phosphatase (Dusp) family contains 25 members and has the ability to remove a phosphate
from an activated MAP kinase located in the nucleus (type I), cytoplasm (type II), or may function in both
11

the nucleus and cytoplasm to dephosphorylate MAPKs (type III) [24, 36]. Dual-specificity phosphatases,
unlike other enzymes with catalytic phosphatase activity, are unique in their ability to remove a phosphate
from either serine, threonine, or tyrosine residues [26].

The founding member of the Dusp family (Dusp1/MKP-1) has been identified in a variety of cells and
tissue types. Dusp1 is a type-1, nuclear dual-specificity phosphatase which preferentially inactivates p38,
but maintains the ability to dephosphorylate ERK and JNK as well, and it is up-regulated in response to
pro-inflammatory stimuli [37]. In 1995, MKP-2 (Dusp4) was identified and was also found to be
expressed in a variety of tissue types; however, since its discovery very little work has been performed to
ascertain the function of Dusp4 in skeletal muscle [38]. The majority of the research on Dusp4 has
focused on its function as a tumor suppressor protein in an assortment of cancers, as well as its role in
immune function [25, 26, 39, 40]. Interestingly, Dusp4 has been shown to be significantly upregulated in
skeletal muscle tissue in response to neurogenic atrophy, while this induction is dramatically blunted in
MuRF1-null animals that are resistant to muscle wasting. Therefore, the primary aims of the research
presented in this thesis were to identify a function for Dusp4 in the skeletal muscle atrophy cascade and
characterize the transcriptional regulation of Dusp4.

Materials and Methods
Cell Culture
C2C12 mouse myoblast cells were obtained from the American Type Culture Collection (Manassas, VA).
The cells were stored in liquid nitrogen until needed. Myoblast cells were thawed at room temperature
and subsequently grown in DMEM (Life Technologies, Grand Island, NY) supplemented with 10% Fetal
Bovine Serum (FBS) (GE Healthcare Hyclone Laboratories, Logan, UT), non-essential amino acids,
Penicillin/Streptomycin, and Gentamicin (Life Technologies, Grand Island, NY). The cells were
maintained in a 6% CO2 humidified chamber at 37°C.
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Cloning of the Dusp4 Gene Promoter
Fragments (500, 1000, and 2000 base pairs) of the Dusp4 regulatory region were amplified by PCR, subcloned into the pGemT-EZ vector (Promega), sequenced, and then moved into the pSEAP2-Basic
(Clontech) reporter vector using the restriction enzymes Kpn1 and Nhe1. The primers used to amplify the
Dusp4 promoter fragments are 2000-F 5′-GCG GTA CCC CGG TGA AAT CGG CCG AGA CTT GC-3′,
1000-F 5′-GCG GTA CCC CTG GAA AGA GGG ATG CGG AAA CTC G-3′, 500-F 5′-GCG GTA
CCG CAC GAA GAA CGA GAT TAA GTC CGG C-3′, and reverse primer 5′-GCG CTA GCG CCG
GCT CTC CCG GGG GAG GGA AGA G-3′. PCR reactions were performed with 1µg of genomic mouse
DNA as well as 0.5µL Taq DNA polymerase according to the manufacture’s protocol (Life technologies,
Grand Island, NY). Thermocycler conditions for promoter amplification were one cycle at 94°C for 2 min
followed by 30 cycles at 94°C for 45 sec, 55°C for 45 sec, and 72°C for 3 min.

Site-directed Mutagenesis
AP-2 Binding Element:
The Dusp4 promoter sequences were obtained from the Ensembl database (www.ensembl.org) and a
putative activator protein 2 (AP-2) binding element located within the Dusp4 500bp regulatory region was
mutated using the primer sequences: (F) 5ʹ-GGT AGT AAT GAC TCT TCC GTG CCC CGG GAG AAG
CAG GC -3ʹ and (R) 5ʹ-GCC GGC TCT CCC GGG GCA CGG AAG AGT CAT TAC TAC C-3ʹ. The
mutagenesis reaction was performed using 100ng of the pSEAP2-Dusp4 Pro-500 reporter construct.
Cycling conditions for mutagenesis were as follows: one cycle at 95°C for 30 sec followed by 18 cycles
at 95°C for 30 sec, 55°C for 1 min, and 68°C for 12 min.

E-box Element:
The mouse Dusp4 promoter sequences were obtained from the Ensembl database (www.ensembl.org) and
six consensus E-box enhancer elements were identified within the 2000bp promoter fragment of Dusp4;
however, only one was conserved between human, rat, and mouse. Primers were designed to mutate the
13

single conserved E-box element: (F) 5ʹ-CTT TTC CTT CGT ACC GAA CGT AGA CCT TAA CCG TC3ʹ and (R) 5ʹ-GAC GGT TAA GGT CTA CGT TCG GTA CGA AGG AAA AG-3ʹ. The mutagenesis
reaction was performed using 400ng of pSEAP2-Dusp4 Pro-2000 plasmid. Cycling conditions for
mutagenesis were as follows: one cycle at 95°C for 30 sec followed by 18 cycles at 95°C for 30 sec, 55°C
for 1 min, and 68°C for 16 min.

C-Terminal Catalytic Phosphatase Domain:
The C-terminal catalytic phosphatase domain of Dusp4 was mutated through site-directed mutagenesis
according to the manufacture’s protocol (Stratagene, La Jolla, CA). The amino acid that was altered was
located within the conserved active site motif (HCxxGxxR) and primers were designed to alter a single
nucleotide from a thymine to a guanine resulting in an amino acid change at position 284 from cysteine to
glycine. The primers used were (F) 5ʹ-GCT GGT TCA CGG CCA GGC CGG C-3ʹ and (R) 5ʹ-GCC GGC
CTG GCC GTG AAC CAG C-3ʹ. The resulting Dusp4 clone was sequenced to confirm the correct
mutation was introduced into the gene.

MuRF1 RING Domain:
The MuRF1 cDNA and protein sequences were downloaded from the PubMed database
(www.Pubmed.org). The MuRF1 protein sequences for rat, mouse, and human were aligned using
sequence alignment tools (http://www.ncbi.nlm.nih.gov). The aligned sequences were used to identify
conserved amino acids for site-directed mutagenesis. Site-directed mutagenesis reactions were performed
according to the manufacture’s protocol (Stratagene, La Jolla, CA). Mutations in the RING domain of the
MuRF1

gene

were

accomplished

by

using

the

following

CTACAGCAACCGTGAGAAGGCCGACTCCAACCACAACC-3ʹ

and

primers:
(R)

(F)

5ʹ5ʹ-

GGTTGTGTTGGAGTCGGCCTTCTCACGGTTGCTGTAG-3ʹ. The resulting MuRF1 clone was
sequenced to confirm the correct mutation was introduced into the gene.
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Amplification and Cloning of Dusp4 cDNA
Total RNA was isolated from homogenized C2C12 mouse myoblast cells using the RNeasy Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer’s protocol. The purified total RNA (0.75-1.5 µg)
was then reverse transcribed using Oligo-dT primers (500µg/mL), dNTP mixture (2.5mM), and nucleasefree sterile water. The mixture was incubated at 65°C for 5 minutes then incubated on ice for 5 minutes.
The mixture was briefly centrifuged and First Strand Buffer (Invitrogen Corporation, Carlsbad, CA), DTT
(0.1M), and Ribonuclease Inhibitor were added according to the manufacturer’s instructions. The mixture
was briefly mixed and incubated at 37°C for 2 minutes, followed by the addition of Moloney Murine
Leukemia Virus (M-MLV) Reverse Transcriptase (Life Technologies, Grand Island, NY). The reaction
was incubated at 37°C for 50 minutes followed by heat inactivation at 70°C for 15 minutes. The Dusp4
cDNA was then amplified via PCR using gene specific primers, cloned into the XhoI/BamHI restriction
sites of pcDNA3.1-zeo plasmid and sequenced to confirm the absence of mutations. Primer sequences for
Dusp4 cDNA amplification are: (F) GCC TCG AGG CTT ACT GCG TTT TGC CGG CGA CAT GG
and (R) GCG GAT CCG GAT TTG GGG TCC AGA GAC GAG TCC.

Cloning the AP-1 Reporter Construct
The canonical sequence for the activator protein 1 (AP-1) response element 5ʹ-TGACTCA-3ʹ was cloned
into the pSEAP2-Promoter plasmid using the MluI restriction site following the manufacture’s protocol
(Sigma Aldrich, St. Louis, MO). Samples were sequenced to confirm insertion of the AP-1 response
element.

Transfections
C2C12 cells were plated at 50,000-75,000 cells per well in 12 well plates and grown to approximately 70%
confluency prior to transfection. One hour prior to transfection the media was removed from the cells and
fresh culture media was added to the wells. 1 µg of total DNA (1µg total DNA/well) was transiently
transfected using Turbofect transfection reagent according to the manufacturer’s instructions (Thermo
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Scientific, Rockford, IL). The DNA mixture consisted of 250 ng/well of indicated reporter construct, 125
ng/well of TK-UAS-β-Galactosidase and 125-250 ng/well of expression plasmids (pcDNA3.1-Dusp4,
pcDNA3.1-Dusp4-C284G mutant, pcDNA3.1-MuRF1, pcDNA3.1-MuRF1-RING-mutant, pcDNA3.1MyoD1, and/or pcDNA3.1-myogenin), and pBluescript plasmid as filler DNA. At 24 hours posttransfection, media was aspirated and fresh media containing 2% FBS (differentiation media) was added
to each well.

Reporter Gene Assays
Secreted alkaline phosphatase (SEAP) reporter gene assays were performed according to the
manufacturer’s protocol (Clontech, Mountain View, CA) 72 hours following the switch to low serum
media (2% FBS). SEAP activity was measured in relative light units (RLU) and corresponds to the
activity of the Dusp4 reporter gene. The resulting data values were normalized to β-galactosidase activity
to correct for variations in transfection efficiency. Each condition was done in triplicate and error reflects
the standard deviation from the mean.

Bioinformatics Analysis
The nucleotide sequence corresponding to the regulatory regions of mouse, rat, and human Dusp4
(Ensembl Transcript ID: ENSMUSG00000031530) from -2000 through the first exon were downloaded
from the Ensembl database (www.ensembl.org), aligned using ClustalW2 alignment tool on the EMBL
website (http://www.ebi.ac.uk/Tools/msa/clustalw2/), and shaded using Boxshade analysis of the
ClustalW2 alignment output data (http://www.ch.embnet.org/software/BOX_form.html). The amino acid
sequences for mouse, rat, and human Dusp4 were downloaded from the Ensembl database and aligned
and shaded as described for the nucleotide sequences above.
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Protein Purification and Western Blot Analysis
C2C12 cells were plated and grown in 10 cm plates and harvested over a time course of 12 days, from
proliferating myoblasts to differentiated myotubes. Following harvest, the cells were lysed using 500µL
of Universal Lysis Buffer (ULB) [50mM Tris, 150mM NaCl, 50mM NaF, 1mM PMSF, 1mM DTT,
10mM β-glycerophosphate, 2mM Sodium Molybdate, and a protease inhibitor cocktail]. The cells were
incubated on ice for 30 minutes and centrifuged at 4°C for 5 minutes at 18,000 × g. The homogenates
were stored at -80°C until needed. Protein concentrations were determined using a Bradford protein assay
method according to the manufacturer’s protocol (BioRad, Hercules, CA). Total protein (100-150µg) was
separated on a 9% SDS-PAGE gel and then transferred overnight to a polyvinylidene difluoride (PVDF)
membrane (EMD Millipore, Billerica, MA). The membrane was Ponceau S stained to ensure efficient
protein transfer was achieved before probing. The membrane was allowed to block for one hour in a
solution of 5% milk + 0.05% Tween in Tris Buffered Saline (TTBS). Following blocking, the membrane
was probed with protein-specific antibodies for Dusp4, MyHC, and α-tubulin (S-18, rabbit polyclonal;
F59, mouse monoclonal; and DM1A, mouse monoclonal, Santa Cruz Biotechnology, Inc.) at a 1:500
dilution for one hour with shaking at room temperature. The membrane was washed 3X with 1X TTBS,
incubated with secondary antibody at a 1:5000 dilution for one hour at room temperature, and then
washed 4X with 1X TTBS. The membrane was incubated for 2 minutes in Pierce ECL western blot
substrate before imaging (Thermo Scientific, Rockford, IL). Imaging was carried out using X-ray film
with Kodak developing and fixing solutions.

Human embryonic kidney 293T cells transfected with either pcDNA3.1-Dusp4 or pEGFP-C1-Dusp4
expression plasmids and then harvested upon confluency and lysed exactly as described for C2C12 cells.
Total protein (25µg-75µg) was separated on a 9% SDS-PAGE gel and analyzed as described above.
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Confocal Fluorescence Microscopy
C2C12 cells were plated onto glass cover slips in 6 cm plates. The cells were washed with 1X PBS and
fresh media was added 1 hour prior to transfection. Cells were transfected with either the empty pEGFPC1 vector or pEGFP-Dusp4 using Turbofect transfection reagent (Thermo Scientific, Rockford, IL)
according to the manufacturer’s protocol. The cells were washed 2X with 1X PBS ~18-24 hours posttransfection, fixed with 4% paraformaldehyde in 0.1M sodium cacodylate, pH 7.6, stained with Draq5 far
red fluorescent dye (Biostatus, Leicestershire, UK) and mounted with Vectashield Hardset Mounting
Medium (Vector Laboratories, Burligame, CA). Images shown were taken with an Olympus Fluoview
FV-1000 confocal Fluorescent microscope with either a Super Apochromat UPLSAPO 20X objective or a
Super Apochromat UPLSAPO 60X-water objective. The GFP and Draq5 images were merged with open
access ImageJ software with the Open Microscopy Environment Bio-formats software plugin tool.

Statistical Analysis
All conditions were performed in triplicate and data are presented as the mean ± the standard deviation.
Statistical analysis was performed by using XL-STAT software program for either a one-way analysis of
variance (ANOVA) for comparison of data to control with an REGW post-test or a two-way ANOVA to
compare data between groups. Values were considered significant at a P-value ≤ 0.05.

Results
Characterization of the Dusp4 Proximal Promoter
Our first objective was to characterize the transcriptional activity and regulation of Dusp4 in skeletal
muscle cells. To that end, segments of the Dusp4 proximal promoter region were cloned into the
pSEAP2-Basic reporter plasmid. The activity, in relative light units (RLU), of the Dusp4 reporter
constructs were then compared to the activity of the empty pSEAP2-Basic reporter, which contained no
regulatory machinery and was used as a negative control. These experiments show that the Dusp4
promoter fragments are active in muscle cells and can be used to evaluate the regulation of this gene in
18

cell culture. The 500bp regulatory region was the most active in cell culture, but the 1000bp and 2000bp
fragments also had significant activity as well (Figure 9). A one-way ANOVA was performed and a
Ryan-Einot-Gabriel-Welsch Multiple Range (REGW) Test showed that there was significant difference
between the activity of the Dusp4 promoter constructs and the pSEAP2-Basic reporter.
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Figure 9. The activity of the Dusp4 promoter fragments compared to the empty pSEAP2-Basic plasmid in
C2C12 mouse myoblasts. C2C12 cells transfected at 70-80% confluency with either the empty pSEAP2-Basic
plasmid or the SEAP reporter plasmid fused to a 500bp, 1000bp, or 2000bp proximal promoter fragment of mouse
Dusp4. Media was sampled 72 hours post- transfection and each condition was performed in triplicate. The samples
were normalized with β-galactosidase activity to correct for variation in transfection efficiency. Error bars represent
the standard deviation. An ANOVA was performed using corrected triplicate values. All pair-wise comparisons
were significantly different (ANOVA; F3,11=150.12; P<0.0001) (a) compared to pSEAP2-Basic, (b) compared to
pSEAP-Dusp4 Pro-500, (c) compared to pSEAP-Dusp4 Pro-1000, (d) compared to pSEAP-Dusp4 Pro-2000.

MuRF1 Inhibits Dusp4 Reporter Gene Activity
The data obtained from comparing changes in gene expression between wild-type and MuRF1-null
animals revealed differences in mRNA expression for Dusp4 following denervation-induced skeletal
muscle atrophy (Figure 6). The blunted induction of Dusp4 mRNA in the MuRF1-null gastrocnemius
tissue samples, at both 3 days and 14 days following sciatic nerve denervation, suggested that MuRF1
may be necessary for full activation of the gene subsequent to a traumatic neurogenic event. Therefore,
we decided to look more closely at the regulation of Dusp4 in order to determine a mechanism by which
MuRF1 might regulate Dusp4 expression.

19

In order to evaluate the transcriptional regulatory mechanisms governing the Dusp4 gene in vitro, 500bp,
1000bp, and 2000bp fragments of the proximal promoter were amplified from genomic mouse DNA and
inserted into the pSEAP2 reporter plasmid. Recombinant Dusp4 reporter gene plasmids were then
subjected to ectopic expression of MuRF1 and changes in reporter gene activity were evaluated. The
Dusp4 500bp regulatory region showed significant repression in response to ectopic expression of
MuRF1 (Figure 10A). A similar pattern of repression by MuRF1 was observed for the 1000bp and
2000bp Dusp4 reporter gene constructs (Figure 10B and C, respectively). The results using the Dusp4
reporter gene constructs suggest that MuRF1 is able to regulate the transcriptional activity of Dusp4 in
C2C12 cells.
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Figure 10. MuRF1 represses Dusp4 reporter gene activity. MuRF1 over-expression results in transcriptional
repression of the (A) 500bp, (B) 1000bp, and (C) 2000bp Dusp4 reporter gene fragments at 72 hours posttransfection. C2C12 cells were transfected at approximately 70-80% confluency with either Dusp4 500bp, 1000bp, or
2000bp promoter fragments fused to the pSEAP2-Basic reporter plasmid with or without a MuRF1 expression
plasmid. The cells were changed to differentiation media (2% FBS) 24 hours following transfection. Samples of
media were taken 72 hours after the switch to 2% media and measured for SEAP activity. The samples were
normalized with β-galactosidase activity to correct for variation in transfection efficiency. Each condition was done
in triplicate and error bars represent standard deviation (Two tailed T-test * p < 0.05, ** p < 0.01, *** p < 0.001).
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Mutagenesis of the Dusp4 AP-2 Binding Element Increases Dusp4 Reporter Gene Activity
There were differences regarding the effect of MuRF1 on Dusp4 between in vitro and in vivo
experimentation models so it was necessary to take a closer look at the Dusp4 promoter region to locate
potential transcription factor binding elements that may provide clarification about Dusp4 gene
expression in response to MuRF1 over-expression in skeletal muscle. A particular region of interest
located within the 500bp regulatory region of Dusp4 was the sequence 5ʹ-CCCTCCCC-3ʹ. This sequence
corresponds to a canonical activator protein 2 (AP-2) binding region that may be important for neural
development and restructuring in vertebrates [41], which provides Dusp4 with a potential function during
neurogenic muscle atrophy. In addition to the AP-2 binding element, there were many additional areas of
interest within the Dusp4 promoter region including CAATT box elements, a FoxO binding element, and
multiple E-box elements (Figure 11).

Figure 11. Dusp4 proximal promoter alignment. Promoter sequences from mouse, rat, and human Dusp4 genes
(2000 base pairs upstream of the transcription start site (+1) through the first exon) were downloaded from the
Ensembl database (www.ensembl.org) and aligned using the Clustal omega algorithm. Identical sequences for the
indicated regions are highlighted in black. Approximate positions of potential transcription factor binding sites are
indicated in the diagram and highlighted in the alignments: Muscle-specific E-box elements CANNTG (Dark blue
square), CAATT box element (Red circle), GC rich region (yellow triangle), FoxO binding element TGTTTA
(Green diamond), and an AP-2 element CCCTCCCCC (Blue pentagon).
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Mutation of the AP-2 binding element resulted in increased Dusp4 Pro-500 reporter gene activity
compared to the wild-type promoter. The increased Dusp4 activity observed in the AP-2 mutant was even
more pronounced in late passage (P18) compared to earlier passage (P7) C2C12 mouse muscle cells
(Figure 12). The confluency of the cells was similar at the time of transfection so the increase in the
pSEAP2-Dusp4 500bp promoter activity for late passage cells could be the result of differences in the
cells as they age and will be investigated in future studies.
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Figure 12. Dusp4 Pro-500 WT and Dusp4 Pro-500 AP-2 mutant gene reporter activity in C2C12 mouse
myoblasts. Overall activity for the two promoter fragments was greater in late passage cells (A) compared to early
passage (B), while the AP-2 mutant had greater activity than the wild-type Dusp4 500bp promoter fragment. Cells
were transfected at approximately 70-80% confluency and the SEAP assay was performed 72 hours posttransfection. The samples were normalized with β-galactosidase activity to correct for variation in transfection
efficiency. Error bars represent standard deviation. A two tailed T-test was performed using the corrected triplicate
data values (* p < .05, *** p < .001).
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The effect of ectopic MuRF1 expression on the wild-type Dusp4 reporter was different than that observed
for the cells transfected with the AP-2 mutant Dusp4 promoter. The AP-2 Dusp4 mutant reporter still
appears to be regulated by MuRF1, however ectopic MuRF1 expression resulted in a 50.5% decrease in
the Dusp4 Pro-500 AP-2 mutant promoter as compared to a 41.4% decrease in the WT Dusp4 (Figure
13). All pair-wise comparisons were statistically significant, with the exception of the wild-type pSEAP2Dusp4 500bp reporter compared to the pSEAP2-Dusp4 AP-2 mutant Dusp4 500bp reporters in response
to ectopic MuRF1 expression. The over-expression of MuRF1 in cells transfected with the AP-2 mutant
Dusp4 promoter construct resulted in expression values back down to levels observed in the WT Dusp4
500bp control promoter series. This can be seen in Figure 13 however, this research study was not
focused on comparing the differences between the WT untreated and the AP-2 mutant Dusp4 promoter in
the presence of MuRF1 over-expression, although this could be evaluated in future studies.
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Figure 13. Dusp4 Pro-500 WT and Dusp4 Pro-500 AP-2 mutant gene reporter activity in response to ectopic
MuRF1 expression in late passage (P18) C2C12 mouse myoblasts. The WT-Dusp4 Pro-500 reporter and Dusp4
Pro-500 AP-2 mutant reporter were evaluated in response to ectopic MuRF1 expression. Both promoter fragments
show repression in response to MuRF1 over-expression. Cells were transfected at approximately 70-80% confluency
and the assay was performed 72 hours following transfection. The samples were normalized with β-galactosidase
activity to correct for variation in transfection efficiency. Error bars represent standard deviation. A two-way
ANOVA was performed using the corrected triplicate data values. All pair-wise comparisons were significantly
different except Dusp4 Pro-500 control and AP-2 mutated Dusp4 Pro-500 + MuRF1 (ANOVA; F3,11
Control=123.02; P<0.0001, ±MuRF1=146.80; P<0.0001, WT Dusp4/AP-2 Mutant Dusp4=190.65; P<0.0001,
MuRF1/AP-2=31.59; P<0.005) (a) compared to pSEAP-Dusp4 Pro-500, (b) compared to pSEAP-Dusp4 Pro-500 +
MuRF1, (c) compared to pSEAP-Dusp4 Pro-500 AP-2 mutant.
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MuRF1 RING Domain Mutant Fails to Repress Dusp4 Reporter Gene Activity
As previously discussed, ectopic expression of MuRF1 represses Dusp4 reporter gene activity. Therefore,
we next decided to determine if the E3 ubiquitin ligase activity is necessary for MuRF1-mediated
repression of Dusp4 reporter gene activity. In addition to exposing myoblasts to wild-type MuRF1, a
MuRF1 mutant was generated to try to identify the mechanism by which MuRF1 may act to alter the
transcriptional machinery of certain genes. The MuRF1 protein contains a RING-Finger domain that is
required for catalytic activity of this E3 ubiquitin ligase. RING domains contain a zinc-finger that has a
consensus sequence of C-X2-C-X[9-39]-C-X[1-3]-H-X[2-3]-C-X2-C-X[4-48]-C-X2-C, C stands for a conserved
cysteine residue, H stands for a conserved histidine residue, and X may be any amino acid. Zinc ions are
known to interact with cysteine and histidine residues forming the RING-Finger domain, which interacts
with ubiquitination enzymes and may help facilitate the ubiquitination process [42]. Mutations were
introduced into the RING domain to determine how MuRF1 may function to regulate transcription
(Figure 14). A catalytically dead MuRF1 protein was generated by mutating two of the cysteine residues
to serine (C39S and C44S) of the RING domain, which have been shown to be important for full catalytic
activity [42].
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Figure 14. Alignment of the MuRF1 amino acid sequence. MuRF1 amino acid sequences from mouse, rat and
human were obtained from the PubMed database (www.PubMed.org). The proteins were then aligned using
sequence alignment tools (http://www.ncbi.nlm.nih.gov). Yellow letters represent the RING (Really Interesting New
Gene) Finger domain, yellow and black arrows show the relevant cysteine residues located within the RING finger
domain, blue letters represent the Bcb (B-box c-terminus) domain, and green letters represent the acidic c-terminal
region. (The black arrows indicate the location of the mutated cysteine amino acids.)

Reporter assays were performed using wild-type MuRF1 or the MuRF1-RING mutant to assess their
ability to regulate the 500bp, 1000bp, and 2000bp proximal promoter regions of Dusp4. The data
obtained from the reporter gene assays show that WT-MuRF1 represses the Dusp4 promoters while the
MuRF1-RING mutant lost the ability to fully repress the Dusp4 reporter constructs (Figure 15).
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Figure 15. MuRF1, but not the MuRF1-RING mutant, represses Dusp4 reporter gene activity. The Dusp4
promoters were negatively regulated by the addition of MuRF1; however, there was a loss of repression observed
with the MuRF1-RING mutant. (A) Dusp4 Pro-500, (B) Dusp4 Pro-1000, and (C) Dusp4 Pro-2000. C2C12 cells were
transfected at 70% confluency before being switched to low serum (2% FBS) media. Samples were taken 72 hours
following media change and performed in triplicate. The samples were normalized with β-galactosidase activity to
correct for variation in transfection efficiency. Graphs represent mean values ± SD. Statistical significance was
evaluated using ANOVA and values were considered significant when P ≤ 0.05 [a) compared to control, b)
compared to WT-MuRF1].
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Myogenic Regulatory Factors Inhibit Dusp4 Reporter Gene Activity
Located within the murine Dusp4 promoter are six putative canonical E-box elements that may be bound
by myogenic regulatory factors (MRF), such as myogenin and MyoD1. MRFs are muscle-specific
transcription factors that are dramatically upregulated in response to neurogenic atrophy. Considering that
the Dusp4 proximal promoter has MRF binding elements, we next decided to determine if MRFs can
modulate Dusp4 reporter gene activity in cultured muscle cells. In addition, we also assessed the effect of
ectopic co-overexpression of MuRF1 and MRFs on Dusp4 reporter gene activity. The results show that
myogenin and MyoD1 repress Dusp4 reporter gene activity when over expressed alone for all promoter
fragments evaluated (Figure 16). Interestingly, the combination of MuRF1 and myogenin overexpression
resulted in a loss of repression compared to overexpression of myogenin alone; however, over-expressing
both MuRF1 and MyoD1 together resulted in a cooperative repressive effect that was greater than the
addition of either MuRF1 or MyoD1 alone (Figure 16). An analysis of variance (ANOVA) was performed
on the corrected triplicate values: Dusp4 Pro-500 ANOVA;
P=0.9754,

myogenin=362.58;

P<0.0001,

MyoD1=581.37;

F5, 17

=145.96; P<0.0001, MuRF1=0.00;

P<0.0001,

P<0.0001, MuRF1+MyoD1=25.32; P=0.003. Dusp4 Pro-1000 ANOVA;
MuRF1=3.39;

P=0.0904,

myogenin=333.03;

P<0.0001,

MuRF1+myogenin=55.51;
F5, 17

=101.10; P<0.0001,

MyoD1=349.77;

P<0.0001,

MuRF1+myogenin=23.81; P=0.0004, MuRF1+MyoD1=0.01; P=0.9116. Dusp4 Pro-2000 ANOVA;

F5, 17

=134.47; P<0.0001, MuRF1=0.50; P=0.4951, myogenin=332.07; P<0.0001, MyoD1=541.35; P<0.0001,
MuRF1+myogenin=59.79; P<0.0001, MuRF1+MyoD1=8.20; P=0.0142. Statistical analysis revealed
there were no significant differences between the pair-wise comparisons upon the addition of ectopic
MuRF1 overexpression alone and the combination of ectopic MuRF1+MyoD1 co-overexpression for
each Dusp4 promoter that was evaluated. This was not a direct focus of the study and may be due to the
fact that upon addition of MuRF1 or MyoD1 alone, repression of the control promoter was observed.
Interestingly, MuRF1 reversed the repression when co-transfected with myogenin, resulting in a null
difference in the statistical analysis (Figure 16 A-C).
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Figure 16. Myogenic regulatory factors inhibit Dusp4 reporter gene activity in C2C12 mouse myoblasts. The
(A) 500bp, (B) 1000bp, and (C) 2000bp fragments of the Dusp4 promoter were fused with the pSEAP2-Basic
reporter. C2C12 mouse myoblasts were transfected at approximately 70-80% confluency before being switched to
low serum media (2% FBS). Samples were taken 72 hours following media change and performed in triplicate. The
samples were normalized with β-galactosidase activity to correct for variation in transfection efficiency. Graphs
represent mean values ± SD. Statistical significance was evaluated using an ANOVA test of the corrected triplicate
values. All pair-wise comparisons were significantly different except Dusp4 Pro-500, Pro-1000, and Pro-2000
following the ectopic addition of MuRF1 alone or when MuRF1+MyoD1 treatment was added. Data was considered
significant when P ≤ 0.05 [a) compared to control, b) compared to MuRF1, c) different from control or MuRF1].

Conserved E-box in the Dusp4 Promoter is Necessary for Full Promoter Activity
In total there are six canonical E-box elements located throughout the murine Dusp4 2000bp promoter
region (Figure 17); however, only one was conserved between mouse, rat, and human (Table 1). The
presence of E-box elements located within the proximal promoter suggests Dusp4 may be important in
muscle tissue. Experiments were performed to see how mutating the single conserved E-box
(CAAATGCGAACG) located within the Dusp4 promoter would alter Dusp4 reporter gene activity in
C2C12 cells.
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Figure 17. Dusp4 promoter sequence alignment comparing the location of the six E-box elements between
human, mouse, and rat. The nucleotide sequence corresponding to the regulatory regions of mouse, rat, and human
Dusp4 (Ensemble Transcript ID: ENSMUSG00000031530) from -2000 through the first exon were downloaded
from the Ensemble database (www.ensemble.org), aligned using ClustalW2 alignment tool on the EMBL website
(http://www.ebi.ac.uk/Tools/msa/clustalw2/), followed by Boxshade analysis of the ClustalW2 alignment output
data (http://www.ch.embnet.org/software/BOX_form.html).

E box Sequence

E box location

CAGATG

-1519

CACATG

-1158

CAGATG

-1072

CATTTG
CAAATG
CAGATG

-1012
-950
-631

Table 1. Location of the E-box elements within the 2000bp regulatory region of Dusp4. There are no known
consensus E-box enhancer sequences within the 500bp region, 3 are located in the 1000bp region, and 6 total are
located within the Dusp4 2000bp promoter. The highlighted red sequence corresponds to the conserved E-box
located in the Dusp4 promoter.

Site-directed mutagenesis of the conserved E-box enhancer element within the Dusp4 2000bp regulatory
region resulted in nearly a complete loss of promoter activity compared to the wild-type Dusp4 Pro-2000
reporter gene (Figure 18). There are 5 other E-boxes that remained intact located within this region, but it
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is apparent that this conserved E-box sequence is necessary for the full functionality of the Dusp4
promoter in skeletal muscle cells. It is unknown if mutating the other E-box sequences would have a
similar effect on gene activity, but it will be evaluated in future studies.
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Figure 18. Conserved E-box mutagenesis abolished activity of the Dusp4 reporter gene in C2C12 myoblasts.
C2C12 mouse myoblasts were transfected with either the WT pSEAP2-Dusp4 Pro-2000 or the pSEAP2-Dusp4 Pro2000 E-box mutant reporter constructs. Cells were transfected at approximately 80% confluency and switched to
low serum (2% FBS) media 24 hours post-transfection. SEAP analysis was performed 72 hours following media
change. The samples were normalized with β-galactosidase activity to correct for variation in transfection efficiency.
Conditions were conducted in triplicate and graphs represent mean values ± SD. Statistical significance was
evaluated using a two-tailed T-test. Data was considered significant when P ≤ 0.05 (*** P ≤ 0.001).

Characterization of Dusp4 Protein Expression in Mouse Myoblasts
Experiments using the pSEAP reporter plasmid revealed that the Dusp4 promoter is active in C2C12
mouse myoblasts. It was next important to determine at what point during the proliferation and
differentiation phases that the Dusp4 protein was being expressed in C2C12 cells. A western blot was
performed using C2C12 cell lysates harvested from proliferation through differentiation phases and 150µg
of total protein lysate was separated on a SDS-PAGE gel and then probed for Dusp4. Dusp4 was only
detectable during the proliferation phase in C2C12 cells. Following a media change to induce
differentiation, the signal for Dusp4 was reduced and was not observed in the developing and
differentiated myotubes (Figure 19).
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Figure 19. Western Blot for Dusp4 from C2C12 protein isolates over a 12 day time course. Dusp4 was expressed
at the protein level in C2C12 cells. Western blot analysis was performed using an antibody against Dusp4 on protein
homogenates from proliferating (P) and differentiated (D) C 2C12 cells harvested over a 12 day differentiation time
course. Cells were maintained in proliferation media (10% serum) and harvested at 1 and 2 days post-plating and the
remaining cells were then switched to differentiation media (2% serum) and harvested at 1, 3, 7 and 10 days postmedia change. Myosin Heavy Chain (MyHC) was analyzed as a marker for skeletal muscle cell differentiation.

Identifying the Sub-cellular Localization of Dusp4 in C2C12 Cells
Previous research has identified Dusp4 as a type-I dual-specificity phosphatase that has the functional
ability to remove a phosphate from either threonine or tyrosine residues of MAP kinases. The type-I
distinction qualifies this protein as having a nuclear sub-cellular localization; however, there has been
very little work performed on Dusp4 in skeletal muscle tissue so we decided to determine where in
muscle cells Dusp4 is localized. Since information from the western blot revealed that Dusp4 protein
expression was greatest when cells were fully confluent, but had not yet begun to fuse and form
myotubes, the cells were transfected with GFP-Dusp4 and imaged during the peak of proliferation. In
order to confirm sub-cellular location, Draq5 was used to identify the nuclear region of the cells. The
results agreed with information from previous research that Dusp4 was indeed a nuclear localized dualspecificity phosphatase as the fluorescence that was observed was exclusively nuclear (Figure 20).
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Figure 20. GFP-Dusp4 is localized to the nucleus of C2C12 mouse myoblast cells. Dusp4 cDNA was fused with
GFP and the plasmid was transfected into C2C12 cells plated on glass cover slips in 6 cm culture dishes at
approximately 60% confluency. GFP-tagged Dusp4 protein expression in C2C12 cells (A and D), Draq5 was used to
identify the nuclear region of the cells (B and E), and the merged images of GFP-Dusp4/Draq5 show nuclear
localization of Dusp4 (C and F).

Dusp4 Negatively Regulates the MAPK Signaling Cascade in Skeletal Muscle Cells
Dusp4 is believed to dephosphorylate different MAPK’s (p38, ERK, and JNK) depending on the cell type
being analyzed. In skeletal muscle, there has been virtually no work done to identify the functional ability
of Dusp4 to regulate the MAP kinase cascade. In order to verify that Dusp4 was able to inactivate the
MAPK pathway, an AP-1 reporter system was created. AP-1 was chosen because it has been identified as
an ERK-activated transcription factor. An AP-1 canonical consensus element was cloned into the
pSEAP2-Promoter reporter plasmid and was tested to confirm that the reporter was active in C2C12 cells
by comparing its activity to that of the empty pSEAP2-Promoter plasmid (Figure 21). The experiment
was conducted in both low serum (2%) and high serum (10%) media to determine the most efficacious
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protocol for evaluating AP-1 reporter activity in mouse muscle cells. Similar trends were observed under
both media conditions and the reporter plasmids were determined to be active in myoblasts (Figure 21).
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Figure 21. AP-1 reporter plasmid is active in C2C12 cultured myoblasts. C2C12 cells were transfected with either
pSEAP2-Promoter or pSEAP2 AP-1 reporter plasmid at 70-80% confluency. Fresh media, either 10% FBS or 2%
FBS was added to the cells 24 hours post-transfection. Samples were taken 48 hours following media change and
performed in triplicate. The samples were normalized with β-galactosidase activity to correct for variation in
transfection efficiency. Graphs represent mean values ± SD. Statistical significance was evaluated using an ANOVA
and values were considered significant when P ≤ 0.05 [a) compared within groups P ≤ 0.01, b) compared between
groups P ≤ 0.01].

Since the AP-1 reporter system was determined to work in C2C12 cells, the next step was to observe how
the ERK-activated transcription factor would behave in response to the overexpression of Dusp4. Cells
were transfected with the AP-1 reporter alone or in combination with an expression plasmid containing
Dusp4 cDNA. Overexpression of Dusp4 resulted in reduced activity of the AP-1 reporter system by
nearly 50%, but did not completely abolish activity (Figure 22).
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Figure 22. AP-1 reporter is repressed by ectopic Dusp4 expression. C2C12 myoblasts were transfected at
approximately 60% confluency with either the pSEAP2 AP-1 reporter alone or in conjunction with an expression
plasmid containing Dusp4-cDNA. The media was changed 24 hours after plating to 2% FBS media and samples
were taken 72 hours after media change and performed in triplicate. The samples were normalized with βgalactosidase activity to correct for variation in transfection efficiency. Graphs represent mean values ± SD.
Statistical significance was evaluated using a two tailed T-test and values were considered significant when P ≤ 0.05
(** P ≤ 0.01).

Mutagenesis of the Dusp4 Phosphatase Domain and the MAPK Binding Domain
The results presented above show that addition of exogenous Dusp4 resulted in reduced AP-1 reporter
activity in vitro, so a phosphatase domain mutant was generated and used to determine if AP-1 reporter
repression requires Dusp4 phosphatase activity. The amino acid that was altered was located within the
conserved active site motif (HCxxGxxR) and was generated by substituting a single nucleotide which
resulted in an amino acid change from cysteine to glycine C284G at that residue (Figure 23).
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Figure 23. Alignment of Dusp4 Protein. Dusp4 protein sequences from mouse, rat and human were downloaded
from the PubMed database (www.PubMed.org) and aligned using Clustal Omega sequence alignment tools
(http://www.ebi.ac.uk/Tools/msa/clustalo/). The Dusp4 protein contains a MAP kinase binding domain (red), a
nuclear localization signal (NLS) (green), and the catalytic phosphatase domain (blue). The highlighted yellow
region indicates highly conserved amino acids of the active site of the phosphatase domain and the purple DCR
motif shows the functional pocket in which dephosphorylation occurs.

After site-directed mutagenesis was performed on Dusp4, the mutant constructs were compared to the
wild-type Dusp4 to evaluate how the loss of catalytic activity would affect the ability of Dusp4 to repress
the AP-1 reporter system. Dusp4 mutants 2 and 4 contained only the expected mutation located within the
catalytic domain and the over-expression of those mutants resulted in a loss of repression by Dusp4 on the
pSEAP2 AP-1 reporter system (Figure 24). In addition to the CG mutation within the C-terminal
domain of Dusp4, a second mutation was introduced into Dusp4 mutant 3 which altered a single
nucleotide (adenineguanine) located within the N-terminal MAPK binding domain. This lone
nucleotide change resulted in an amino acid switch at position 119 from an alanine (non-polar) to a serine
(polar) residue. The result was that this Dusp4 mutant regained the ability to repress the AP-1 reporter
system in a level similar to wild-type Dusp4 by likely acting in a dominant-negative fashion (Figure 24).
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Figure 24. Dusp4 repression of an AP-1 reporter requires catalytic phosphatase activity. C2C12 myoblasts were
transfected at approximately 70% confluency with either the pSEAP2 AP-1 reporter alone or in conjunction with
WT-Dusp4 or the Dusp4 C-terminal mutants. The media was changed approximately 24 hours after plating to 2%
FBS media and samples were taken 72 hours after media change and performed in triplicate. The samples were
normalized with β-galactosidase activity to correct for variation in transfection efficiency. Graphs represent mean
values ± SD. Statistical significance was evaluated using an ANOVA and values were considered significant when P
≤ 0.05 [a) compared to control P ≤ 0.05, b) compared to WT-Dusp4 P ≤ 0.05, c) compared to Dusp4-Mutant 3 P ≤
0.001). Dusp4 mutant constructs 2 and 4 contained only the mutation within the catalytic domain (C284G). Dusp4
mutant construct 3 also acquired a secondary mutation within the N-terminal MAPK binding domain (A119S).

We next decided to evaluate if the repression observed by mutant 3 (double mutant) could be enhanced in
a dose-dependent manner. Wild-type Dusp4, Dusp4 mutant 4 (single mutant), and Dusp4 mutant 3
(double mutant) were analyzed at varying concentrations from 125ng to 500ng. The data show that
increasing the concentration of expression plasmids for Dusp4 did result in greater repression at higher
concentrations; however, the Dusp4 catalytic mutant was not able to repress AP-1 to the same extent as
the wild-type, while the double mutant showed a similar repression to WT-Dusp4 at all concentrations
(Figure 25).
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Figure 25. Dusp4 represses the pSEAP2 AP-1 reporter in a dose dependent manner. C2C12 mouse myoblasts
were transfected at 70-80% confluency with either the pSEAP2 AP-1 reporter alone or in conjunction with WTDusp4 cDNA or the cDNA of the Dusp4 C-terminal mutants (Dusp4 mutant 4-phosphatase domain only, Dusp4
mutant 3-phosphatase domain and MAPK binding domain) at incremental increases in concentration ranging from
125ng-500ng. The media was changed approximately 24 hours after plating to 2% FBS and samples were taken 72
hours after media change and performed in triplicate. The samples were normalized with β-galactosidase activity to
correct for variation in transfection efficiency. Graphs represent mean values ± SD. Statistical significance was
evaluated using an ANOVA and values were considered significant when P ≤ 0.05 (* P ≤ 0.05, ** P ≤ 0.01, **** P
≤ 0.0001).

Discussion
MuRF1 has long been characterized as a marker for skeletal muscle atrophy due to its increased
expression in response to a variety of atrophy-inducing stimuli [11]. The research performed in this study
suggests that MuRF1 may also be able to transcriptionally regulate expression of certain atrophy-induced
genes, including Dusp4. Microarray data from MuRF1-null (KO) and wild-type (WT) littermates show
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differential gene expression following denervation. In WT animals, MuRF1 expression returned to
baseline levels by day 14 post-denervation, but in the KO-animals β-galactosidase expression remained
up-regulated following denervation, which shows that the MuRF1 promoter was still active and
responsive to denervation (Figure 3) [18]. Additionally, there was differential Dusp4 gene expression
observed between the wild-type (WT) and MuRF1-null (KO) animals, at both 3 days and 14 days, under
neurogenic atrophy conditions (Figure 6). It was the purpose of this study to establish a potential model to
explain the how MuRF1 may transcriptionally regulate Dusp4 gene expression and to characterize a
potential role of Dusp4 in skeletal muscle.

Dusp4 is part of an elaborate ligand-activated signal transduction cascade known as the MAP kinase
pathway. Dusp4 is widely expressed in many tissues types such as the pancreas, stomach and prostate
[43]. Furthermore, research has been conducted in many cell lines, other than skeletal muscle, to confirm
that dual-specificity phosphatases are important regulators of cell proliferation, growth, and apoptosis [28,
36, 44]. While there is limited information on the direct role dual-specificity phosphatases (Dusp’s) may
play in the development of skeletal muscle tissue, type 1 Dusp’s including Dusp1, Dusp2, and Dusp5
have been the focus of research involving cardiac muscle [45, 46]. The research conducted in those
studies focused on the ability of nuclear Dusp’s to regulate MAP kinase signaling in cardiac myopathies.

Similar findings regarding the regulation of MAPK kinase signaling and cell growth for type 1 nuclear
localized Dusp’s have been at the heart of immunology research for years. Dusp1 has been found to
regulate glucose metabolism and maintain cellular homeostasis, depending on the signaling input from
surrounding cells [47, 48]. Dusp2 (PAC-1) positively regulates the function of immune cells and helps to
control the inflammatory response [49]. Additionally, Dusp5 has also been reported to play a role in the
development and maintenance of T-cells through MAP kinase signaling [50]. Since Dusp4 is also a type 1
nuclear phosphatase, it is believed to also play a role in the regulation and maintenance of certain tissues,
including that of skeletal muscle. While not a focus of this study, it was observed that when C2C12 mouse
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myoblasts were transfected with plasmids containing the cDNA for Dusp4 the individual cells appeared
smaller and began to shift toward a differentiated state more quickly than non-transfected cells,
suggesting that Dusp4 may regulate the growth and proliferation status of skeletal muscle cells as well
(data not shown).

There is little information regarding the transcriptional regulation and downstream targets of Dusp4 in
skeletal muscle. This thesis is focused on understanding how MuRF1 may regulate Dusp4 expression
under neurogenic atrophy conditions. Dusp4 expression was induced at both 3 days and 14 days
following denervation in wild-type mice, but there was blunted Dusp4 induction in the MuRF1-KO
animals (Figure 6) [18]. The transcriptional regulation of Dusp4 was examined by fusing fragments of the
promoter region to the pSEAP2 reporter gene and testing the response in the presence of ectopic MuRF1
expression. In vitro studies using C2C12 myoblasts show that MuRF1 represses Dusp4 promoter activity,
suggesting a possible transcriptional regulatory role for MuRF1 in Dusp4 expression.

Many of the genes that showed differential expression following denervation in MuRF1-KO and WT
animals from the microarray, including Dusp4, contain important regulatory regions such as an activator
protein 2 (AP-2) binding element and E-box enhancer sequences. AP-2 regulation has been most
extensively studied for its importance in neural development and in neural restructuring in vertebrate
organisms [41]. The presence of the AP-2 regulatory region in the Dusp4 regulatory region suggests a
possible functional role for Dusp4 during neurogenic skeletal muscle atrophy. A possible function of
Dusp4 during neurogenic atrophy could center on reorganization of the neuromuscular junctions
following a denervation event in an attempt to reestablish neural connections between the muscle tissue
and the nervous system in order to prevent muscle wasting. In the central nervous system, AP-2 proteins
are necessary for proper embryonic development and are evolutionarily conserved in flies, amphibians,
and birds [51]. Whether the AP-2 element within the Dusp4 promoter functions to control this gene in
response to molecular signaling following denervation is still unclear, but it is possibly important in the
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repair process following denervation in order to repair muscle damage and reduce muscle wasting. Sitedirected mutagenesis of the AP-2 binding element within the Dusp4 promoter resulted in increased
activity of the Dusp4 Pro-500 reporter gene compared to the WT-Dusp4 Pro-500 reporter gene (Figure
12); however, this work was conducted under non-denervation conditions. Further studies using tissue
samples isolated from denervated skeletal muscle could provide more insight on whether this particular
AP-2 sequence associated with Dusp4 is in fact necessary for the functionality of myoblast proliferation
and differentiation following injury. The ability of MuRF1 to repress Dusp4 activity was not greatly
affected by mutating the AP-2 binding element within the promoter. Exogenous MuRF1 expression
resulted in a 50% decrease in the Dusp4 Pro-500 AP-2 mutant promoter as compared to a 38% decrease
in the WT Dusp4 (Figure 13).

The addition of exogenous WT-MuRF1 resulted in significant repression on all of the Dusp4 reporter
constructs (Figure 10). Experiments performed by exogenously expressing a catalytically dead MuRF1RING mutant resulted in a complete loss of repression of the 500bp Dusp4 reporter construct and a slight
loss of repression for the 1000bp and 2000bp Dusp4 reporter gene fragments (Figure 15). One major
difference between the Dusp4 regulatory regions that were tested was the presence or absence of E-box
enhancer elements. The Dusp4 Pro-500 construct contains no consensus E-boxes and there was a
complete loss of repression in response to ectopic expression of the MuRF1-RING mutant. It appeared
that there may be a connection between MuRF1’s ability to transcriptionally regulate Dusp4 and the
presence or absence of E-box elements located within the promoter. Since transfection experiments with
MuRF1, myogenin, or MyoD1 alone showed repression of the Dusp4 promoter constructs, myogenin and
MyoD1 were tested in combination with MuRF1 to determine if a cooperative regulation and further
repression of the Dusp4 reporter could be achieved. Myogenin or MyoD1 alone were able to repress all
Dusp4 promoter fragments, including the 500bp region that lacks E-box elements (Figure 16). Other
research performed with promoter fragments for genes which code for acetylcholine receptor subunit
genes, TGF-β, and TTC39C (tertatricopeptide repeat domain 39C) have shown that there may be a
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cooperation between the myogenic regulatory factors and MuRF1 in transcriptional regulation; although
the results have shown both cooperative repression and activation depending on the particular gene being
studied (unpublished data). There is also a strong possibility that other transcription factors, such as E
proteins (E12 and E47), HEB (human basic helix-loop-helix factor), myf5 (myogenic factor 5), and PBX1 (Pre B cell leukemia homeobox 1), may participate in the regulatory effects observed following the
addition of myogenin and MyoD1 in vitro [20]. Over-expressing both MuRF1 and myogenin resulted in a
loss of Dusp4 repression, compared to ectopic expression of myogenin alone. However, when MuRF1
and MyoD1 were co-overexpressed there was a cooperative repressive effect resulting in greater
repression than was observed for either factor alone (Figure 17). Myogenin and MyoD1 show increased
expression following denervation in mice (Figure 5), so the results from these experiments suggest that
Dusp4 expression may be reduced by MRFs during atrophy, which may lead to myoblast fusion and
myotube development in an attempt to repair or replace some of the damaged tissue. Dusp4 was not the
only gene for which this result has been observed. Unpublished data for Nip30 (NEFA interacting nuclear
protein 30), Rspry1 (RING finger and SPRY domain containing 1), and TTC39C demonstrate these genes
are also cooperatively regulated by MuRF1 and MRFs. These results indicate that while other
transcription factors may be involved, there is a potential interaction between MRFs and MuRF1 that has
not been previously identified in the transcriptional regulation of neurogenic atrophy-induced gene
expression.

The presence of the putative E-box elements, which can be bound by muscle-specific transcription
factors, in the Dusp4 promoter suggest that this particular gene is expressed in muscle and is important in
skeletal muscle development. It is known that other muscle related genes contain E-box elements within
their promoter regions including Musk (muscle creatine kinase) and desmin [21]; however, the conserved
E-box elements may be even more important for the overall regulation of the gene than the number of Ebox sequences. Research has not been conducted to determine if the number of E-box elements present
within the promoter region of a gene directly correlates with gene regulation, as many genes retain
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evolutionarily conserved regions that no longer function in the regulation of a particular gene. Sitedirected mutagenesis on the single conserved E-box element located approximately 950bp upstream from
the start of transcription resulted in a significant reduction in the activity of the Dusp4 Pro-2000 reporter
gene (Figure 18); however, the E-box mutant promoter is still negatively regulated by myogenin and
MyoD1, possibly due to the non-conserved functional E-box sequences still present in this promoter
fragment.

In addition to trying to better elucidate a mechanism for the transcriptional regulation of Dusp4 by
MuRF1, we also took a closer look at the Dusp4 gene product in order to better understand its function in
skeletal muscle. Dusp4 has been studied in a variety of other cells and tissues for its role in apoptosis and
as a tumor suppressor protein [25, 40], but very little work has centered on the function of Dusp4 in
skeletal muscle. Work performed using human umbilical vein endothelial cells (HUVEC) showed that
over expression of Dusp4 resulted in decreased JNK-dependent activation of pro-inflammatory cytokines
and reduced apoptosis [40]. It has been determined that Dusp4 is silenced through epigenetic
hypermethylation of the gene’s promoter in malignant tumors of the nervous system called gliomas,
resulting in significant development of additional glioblastomas [25]. These research findings suggest a
role for Dusp4 in regulating cellular proliferation, but it is unclear if Dusp4 may have the ability to
potentially initiate differentiation in committed cell lines.

Since it appeared that Dusp4 may function in an anti-proliferative role in other cell lines, we wanted to
determine when Dusp4 is being expressed in C2C12 muscle cells. Western blots of C2C12 cell lysates over
a 12 day time course revealed that the Dusp4 protein was only present under proliferating conditions
(Figure 19). Data from the Western blot suggest that the function of Dusp4 in skeletal muscle may be to
signal the end of proliferation and trigger myotube differentiation. In addition to identifying when the
Dusp4 protein was expressed in skeletal muscle cells, we also wanted to confirm that the Dusp4 protein
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was localized to the nucleus of C2C12 myoblasts, which was not surprising because Dusp4 is a type-I dualspecificity phosphatase, meaning it possesses an N-terminal nuclear localization signal (Figure 20).

Determining a potential function of Dusp4 in skeletal muscle was accomplished by designing an AP-1
reporter system, which was used to assess MAP kinase signaling pathway activity in response to ectopic
over expression of Dusp4. The AP-1 reporter was more active under proliferative conditions compared to
differentiation conditions, which is to be expected since proliferating cells are maintained in a higher
percentage of growth serum (Figure 21). AP-1 is an ERK-activated transcription factor and so this
allowed us to determine that Dusp4 is able to negatively regulate the ERK signaling cascade in C 2C12
cells [52]. The data suggest that Dusp4 was able to dephosphorylate ERK in C2C12 cells, indicated by a
reduction in AP-1 reporter activity following over expression of Dusp4 (Figure 22). Since wild-type
Dusp4 was able to inactivate an ERK-regulated transcription factor, site-directed mutagenesis was
performed on the catalytic phosphatase domain of Dusp4 to abolish its ability to dephosphorylate MAP
kinases. The catalytically dead Dusp4 mutants that were generated lost the ability to repress pSEAP2-Pro
AP-1 reporter activity, suggesting that intact catalytic function was needed to dephosphorylate ERK in
C2C12 cells (Figure 24). However, the Dusp4 double-mutant (C-terminal catalytic and N-terminal MAPK
binding domain mutant) regained its ability to repress AP-1 activity and showed greater repression than
WT Dusp4, even though it lacks phosphatase activity. The repression of the AP-1 reporter in response to
the Dusp4 double mutant is not the result of dephosphorylation but may be the result of the mutant Dusp4
interacting with the activated MAP kinase in a dominant-negative fashion. Further research into how the
MAPK binding domain mutation affects the function of Dusp4 will need to be conducted to better
understand the repression observed in the AP-1 reporter system.

Conclusions
In summary, this thesis work helps to contribute to a better understanding of the transcriptional regulation
of Dusp4 and its activation following denervation-induced muscle atrophy. It is possible that Dusp4 may
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be involved in controlling the proliferation status of mouse myoblasts and it may promote the cellular
differentiation to myotubes through the negative regulation of the MAP kinase signaling pathway. The
work presented here identifies MuRF1 as a potential transcriptional regulator as well as provides evidence
that ERK might be a target of Dusp4 dephosphorylation in skeletal muscle.
Work with C2C12 mouse myoblasts reveals that the Dusp4 promoter is transcriptionally active in muscle
cells and is negatively regulated by exogenous MuRF1 expression. Dusp4 is activated in response to
neurogenic atrophy in mice and the full activation appears to be dependent on the presence of MuRF1.
These findings appear to conflict; however, there are many differences between in vivo and in vitro
conditions, including vascular and neural signals as well as signaling from other transcription factors,
including myogenin and MyoD1 that would be present following denervation and could account for these
differences. Further work will be needed to elucidate the complete role of Dusp4 in skeletal muscle
wasting.
Myogenic regulatory factors, including myogenin and MyoD1, were also found to repress Dusp4 reporter
activity likely through interaction with one of the E-box enhancer elements located upstream from the
start of Dusp4 transcription. It is possible that the repression observed due to MuRF1 may be in part
through a mechanism involving interaction with these MRFs at the promoter. Reporter assays using a
catalytically dead MuRF1 construct show that it is the catalytic ubiquitination function of MuRF1 that
appears to be important for the repression of the Dusp4 reporter gene constructs, since the MuRF1-RING
mutant was not able to negatively regulate the reporter genes in a fashion similar to WT-MuRF1.
Additionally, the conserved E-box element within the Dusp4 promoter was determined to be necessary
for the activation of this gene in skeletal muscle cells. The findings presented in this thesis provide
support for MuRF1 as a potential transcriptional regulator of Dusp4 gene expression. There is still work
that needs to be done in order to confirm the mechanism by which MuRF1 regulates gene expression in
skeletal muscle; however, one possible mechanism may occur through an interaction between MRFs and
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MuRF1 that ultimately alters MRF binding of E-box elements and future studies will be conducted in
order to determine if this potential model is correct.
Future Directions
Site-directed mutagenesis of non-conserved E-box elements
In addition to the conserved E-box enhancer element that was mutated in the Dusp4 2000bp promoter
region, there are five other non-conserved E–box elements that exist for the mouse Dusp4 gene. Four of
the five E-box elements match the sequence determined to be most important for regulation by MRF’s
[20]. It is unclear if mutating any of the non-conserved E-boxes will have the same effect on Dusp4
promoter activity or if the repressive effects of myogenin and MyoD1 will be lost if certain E-box
elements are no longer functional. Site-directed mutagenesis of the non-conserved E-box elements will be
performed to determine their necessity and function in the transcriptional regulation of Dusp4.

Site-directed Mutagenesis of the Dusp4 NLS
The N-terminal nuclear localization signal (NLS) is what characterizes Dusp4 as a type-I dual-specificity
phosphatase. The sequence has been identified as RRRAK [53]. The basic residues arginine (R) and
lysine (K) have been identified as being necessary for nuclear translocation, while the spacer amino acid,
alanine (A), appears to be important, but mutations in this region do not affect the ability of proteins to
move into the nucleus [54]. Therefore, the final lysine (K) residue of the NLS, at position 82, will be
mutated to glycine (G). By preventing Dusp4 from entering the nucleus, it will provide an opportunity to
evaluate C2C12 cell proliferation and differentiation rates which will improve our understanding of Dusp4
function during muscle cell proliferation and differentiation.

Determine Dusp4 target substrate specificity in C2C12 cells
The AP-1 reporter system that was designed for this thesis project helped confirm the function of Dusp4
as a MAPK phosphatase in C2C12 cells. Since AP-1 is an ERK-activated transcription factor, the
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repression of the AP-1 reporter system that was observed following exogenous Dusp4 expression
validated Dusp4 in the dephosphorylation and inactivation of the MAP kinase ERK signaling cascade.
While this information is useful, it does not show whether Dusp4 has the ability to inactivate other MAP
kinase pathways, such as JNK and p38, in skeletal muscle. In order to determine if Dusp4 can also
regulate the activity of those MAPK’s, reporter systems that are JNK-specific and p38-specific will need
to be created so that a complete understanding of Dusp4 target proteins can be determined in skeletal
muscle.

Site-directed Mutagenesis of the MAPK binding domain
The Dusp4 double mutant, containing the N-terminal MAPK binding domain and C-terminal catalytic
domain mutations, showed differences from both the WT Dusp4 and Dusp4 C-terminal catalytic mutant
in its ability to repress AP-1 reporter activity. In order to better determine the necessary amino acid
residues that are important for Dusp4 functionality, a MAPK binding domain only mutant will be
generated. This Dusp4 mutagenesis will only focus on altering the alanine to serine (A-119-S) residue
located within the N-terminal MAPK binding domain to determine if that amino acid is necessary for the
binding of Dusp4 to MAP kinases that enter the nucleus.

siRNA knockdown of Dusp4 in C2C12 cells
Small-interfering RNA (siRNA) targeting Dusp4 will be engineered to evaluate how the C 2C12 cells will
respond to reduced levels of the protein. In addition to monitoring the growth rates of the cells, western
blot analysis will be performed to look for changes in markers of differentiation (i.e. MyHC). Several
different oligo sequences will be used to analyze whether a specific siRNA sequence has a greater ability
to reduce Dusp4 protein levels in skeletal muscle cells. Effective siRNA-mediated Dusp4 protein
knockdown will be monitored by western blotting for Dusp4 in C2C12 cells.
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Transgenic Dusp4 and Dusp4-KO mouse models
A wealth of information can be determined from experimentation with C2C12 cells and it can provide
insight into molecular mechanisms by teasing out other factors; however, in vitro research can only
advance so far the understanding of denervation-induced skeletal muscle atrophy and the role of Dusp4 in
the process of muscle wasting, therefore transgenic Dusp4 mice and Dusp4-KO animals will be
considered in the future. Work has already been performed using mouse embryonic fibroblasts (MEF’s)
derived from Dusp4-KO mice to determine that cell proliferation rates were markedly reduced [27];
however, muscle cells were not evaluated in that study. Dusp1 is also a type-1 dual-specificity
phosphatase that may compensate for the reduction in Dusp4 protein expression [37]. Research performed
using Dusp1/Dusp4 double-null mice shows unrestrained activation of the MAP kinase p38, resulting in
the development of cardiomyopathy [55]. By over expressing the Dusp4 protein or removing it from the
mouse genome, the role of this gene product and its connection to other physiological systems, which
cannot be mimicked in cell culture studies, can be evaluated.

All of the future directions previously described will help to not only provide additional knowledge
regarding the role and function of Dusp4 in skeletal muscle, but it will also contribute to our
understanding of how this gene is induced following sciatic nerve denervation and the role MuRF1 may
play both in that activation and as a transcriptional regulator in general. The more information that can be
obtained regarding Dusp4, a crucial member of the MAPK signaling cascade involved in cellular
proliferation, the better our understanding will be of the unseen events that occur during the process of
skeletal muscle atrophy as well as the impact of MuRF1 on the transcriptional regulation of Dusp4.
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